Eculizumab improved weakness and taste disorder in thymoma-associated generalized myasthenia gravis with anti-striational antibodies: A case report
Open Access
- 1 March 2019
- journal article
- Published by Elsevier in eNeurologicalSci
- Vol. 14, 72-73
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Eculizumab: A Review in Generalized Myasthenia GravisDrugs, 2018
- Thymectomy during Myasthenic Crisis under Artificial RespirationAnnals of Thoracic and Cardiovascular Surgery, 2018
- Pathophysiology and immunological profile of myasthenia gravis and its subgroupsCurrent Opinion in Immunology, 2017
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyThe Lancet Neurology, 2017
- Overlooked non-motor symptoms in myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Taste disorders in myasthenia gravis: a multicenter cooperative studyEuropean Journal of Neurology, 2012
- Three Types of Striational Antibodies in Myasthenia GravisAutoimmune Diseases, 2011
- Striational Antibodies in Myasthenia GravisArchives of Neurology, 2005
- Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravisJournal of Neuroimmunology, 2000